Cilnidipine 5 mg (Generic)

Product Overview

Cilnidipine 5 mg (Generic) is a pharmaceutical tablet formulated to manage elevated arterial pressure in adult patients diagnosed with essential hypertension. Manufactured by J. B. Chemicals and Pharmaceuticals Ltd, the product is supplied in blister packs containing ten tablets per strip, with available pack sizes of 30, 60, and 90 tablets to accommodate varying treatment durations. The active ingredient, cilnidipine, belongs to the dihydropyridine class of calcium‑channel blockers and is presented at a standardized strength of 5 mg per tablet. This medication is intended for oral administration and should be integrated into a comprehensive cardiovascular risk reduction strategy that includes dietary modification, regular physical activity, and routine monitoring of blood pressure levels.

What is Cilnidipine 5 mg (Generic)

Cilnidipine is a synthetic dihydropyridine derivative that functions as a selective antagonist of L‑type voltage‑gated calcium channels located primarily in vascular smooth muscle and cardiac myocytes. By binding to these channels, cilnidipine inhibits calcium influx, leading to relaxation of arterial walls and a consequent reduction in peripheral vascular resistance. The 5 mg dosage represents the most commonly prescribed strength for once‑daily use in the management of hypertension. As a generic product, it meets the same rigorous quality, safety, and efficacy standards required of the reference brand, offering a cost‑effective alternative without compromising therapeutic performance.

Uses and Benefits

The primary therapeutic use of Cilnidipine 5 mg is the reduction of high blood pressure, a condition that affects an estimated one in three adults worldwide. Lowering systolic and diastolic pressures decreases the risk of cerebrovascular accidents, ischemic heart disease, and chronic kidney disease. Clinical studies have demonstrated that regular use of cilnidipine can achieve average reductions of 10–15 mm Hg in systolic and 6–10 mm Hg in diastolic measurements when administered consistently. In addition to its blood‑pressure‑lowering effect, cilnidipine has a favorable metabolic profile, showing minimal impact on glucose or lipid levels, which makes it suitable for patients with concomitant metabolic syndrome. The medication is also associated with a lower incidence of peripheral edema compared with some other calcium‑channel blockers, enhancing patient comfort and adherence.

How It Works

The mechanism of action of cilnidipine centers on the selective blockade of L‑type calcium channels in vascular smooth muscle cells. Inhibition of calcium entry leads to a relaxation of arterial smooth muscle, resulting in vasodilation and a subsequent decline in systemic vascular resistance. This vasodilatory effect is dose‑dependent and manifests within one to two hours after oral administration, peaking around six hours. The drug exhibits a relatively long elimination half‑life, allowing for once‑daily dosing. Importantly, cilnidipine’s selectivity for vascular over cardiac tissue contributes to a reduced frequency of reflex tachycardia, a common side effect observed with non‑selective calcium‑channel antagonists. For a detailed scientific overview, refer to the NIH’s resource on calcium‑channel blockers: NIH Calcium‑Channel Blocker Overview.

Dosage Guidelines

Dosage of Cilnidipine 5 mg must be individualized based on the patient’s baseline blood pressure, renal function, and comorbidities. The standard initial regimen consists of one tablet taken orally once daily, preferably at the same time each day to maintain steady plasma concentrations. If further blood‑pressure reduction is required, the prescribing clinician may adjust the dose upward, but should not exceed the maximum recommended daily dose without medical supervision. Patients with moderate hepatic impairment are advised to start at a lower dose, such as 2.5 mg if available, and to monitor liver function tests periodically. It is essential that patients do not alter the prescribed dose without consulting their healthcare provider, as abrupt changes can lead to unpredictable blood‑pressure fluctuations. For additional guidance on hypertension management, see the American Heart Association’s lifestyle recommendations: American Heart Association.

Side Effects

Like all pharmaceutical agents, Cilnidipine 5 mg may be associated with adverse reactions, although most are mild and transient. The most frequently reported side effects include mild headache, dizziness, flushing, and peripheral edema, particularly in the ankles and lower extremities. Less common but clinically significant adverse events comprise bradycardia, constipation, and elevated liver enzyme levels, which necessitate periodic laboratory monitoring. Rarely, patients may experience allergic skin reactions such as rash or pruritus. If any of these symptoms persist beyond a few days or worsen, the medication should be discontinued and a healthcare professional contacted promptly. For a comprehensive side‑effect profile, consult the FDA’s drug label database: FDA Drug Label Database.

Warnings and Precautions

Prior to initiating therapy with Cilnidipine, clinicians should assess patient history for contraindications such as severe hepatic impairment, cardiogenic shock, or known hypersensitivity to dihydropyridine derivatives. Concomitant use with certain medications, including strong CYP3A4 inhibitors or inducers, may alter cilnidipine plasma levels and should be avoided or dose‑adjusted accordingly. Patients with a history of heart failure should be monitored closely, as calcium‑channel blockers can exacerbate certain forms of the disease. Pregnant or lactating women should only use the medication if the anticipated benefit justifies the potential risk, and a discussion with a qualified obstetrician is recommended. Additionally, alcohol consumption should be limited, as it may potentiate the hypotensive effect. For detailed safety information, refer to the Drugs.com entry on cilnidipine: Drugs.com Cilnidipine Information.

Frequently Asked Questions

Question 1: What is the typical starting dose of Cilnidipine 5 mg?
Answer: The usual starting dose is one tablet taken once daily, as prescribed by a healthcare professional.

Question 2: Can Cilnidipine be taken with food?
Answer: Yes, the tablet can be taken with or without food; however, consistent administration with meals is recommended for optimal absorption.

Question 3: How long does it take to see a reduction in blood pressure after starting treatment?
Answer: Blood‑pressure lowering effects are typically observed within one to two weeks of regular use, with maximal effect achieved after four to six weeks.

Question 4: Is Cilnidipine safe for patients with diabetes?
Answer: Clinical data indicate that cilnidipine does not adversely affect glycemic control, making it a suitable option for patients with type 2 diabetes when prescribed appropriately.

Question 5: What should I do if I miss a dose?
Answer: If a dose is missed, the patient should take it as soon as remembered unless it is near the time of the next scheduled dose; in that case, the missed dose should be skipped and the regular dosing schedule resumed.

Related Products

• Nicardia XL 30 Mg (Nifedipine)
• Cilacar (Cilnidipine)
• Cilacar 5 mg (Cilnidipine)
• Cilacar 10mg (Cilnidipine)
• Cilacar 20mg (Cilnidipine)
• Cilacar T (Cilnidipine/Telmisartan)
• Arkamin 100 (Clonidine)
• Abel 40 mg (Azilsartan Medoxomil)
• Metrogyl Gel (Metronidazole)
• Metrogyl Tablet (Metronidazole)
• Metrogyl 200mg (Metronidazole)
• Metrogyl 400mg (Metronidazole)